This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Icon PLC (ICLR) Soars 4.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Icon PLC (ICLR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Elevance Health (ELV) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Elevance Health (ELV) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
UnitedHealth Unit (UNH) Wins Medicaid Deal to Serve Kansas
by Zacks Equity Research
UnitedHealth Group (UNH) receives a contract from the State of Kansas to provide enhanced care to beneficiaries of the KanCare program and gain a greater Medicaid customer base.
Icon PLC (ICLR) Up 6.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Elevance (ELV) Rises 14.9% YTD: What Lies Ahead for Investors?
by Zacks Equity Research
Elevance (ELV) continues to focus on increasing shareholder value with consistent dividend payouts and stock repurchases.
Here's Why Elevance Health (ELV) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Elevance Health (ELV) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Elevance Health (ELV) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Elevance Health (ELV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
If You Invested $1000 in Elevance Health a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
HCA Healthcare's (HCA) Q1 Earnings Beat on Rising Admissions
by Zacks Equity Research
HCA Healthcare's (HCA) quarterly results gain from broad volume-based growth along with a rising number of surgeries. Rising expenses act as a partial offset.
Here's Why Elevance Health (ELV) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Industry Outlook Highlights Elevance Health Medpace and Doximity
by Zacks Equity Research
Elevance Health, Medpace and Doximity are part of the Zacks Industry Outlook article.
Community Health (CYH) Q1 Earnings Top on Better Occupancy Rates
by Zacks Equity Research
Community Health's (CYH) first-quarter results benefit from improved occupancy and reimbursement rates. However, declining admissions partially offset the positives.
Molina Healthcare (MOH) Q1 Earnings Beat on Growing Membership
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 results reflect strong premium revenue growth. It continues to estimate adjusted EPS at a minimum of $23.50 for 2024.
Universal Health (UHS) Q1 Earnings Beat on Rising Patient Days
by Zacks Equity Research
Universal Health's (UHS) first-quarter results benefit from improved patient days in both segments. However, higher expenses partially offset the positives.
All You Need to Know About Elevance Health (ELV) Rating Upgrade to Buy
by Zacks Equity Research
Elevance Health (ELV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ELV or AVTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. AVTR: Which Stock Is the Better Value Option?
3 Medical Services Industry Stocks to Buy as Nursing Market Booms
by Urmimala Biswas
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, MEDP and DOCS are set to gain the most. However, staffing shortages continue to put brakes on growth.
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Elevance Health (ELV) have performed compared to their sector so far this year.
Why Elevance Health (ELV) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Analyst Blog Highlights Meta Platforms, Elevance Health, Canadian Natural Resources, The Coca-Cola and The Progressive
by Zacks Equity Research
Meta Platforms, Elevance Health, Canadian Natural Resources, The Coca-Cola and The Progressive are part of the Zacks top Analyst Blog
How Should You Play Centene (CNC) Ahead of Q1 Earnings?
by Zacks Equity Research
Centene's (CNC) first-quarter earnings are likely to reflect significant growth in commercial marketplace membership.
Top Research Reports for Meta Platforms, Elevance Health & Canadian Natural Resources
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Elevance Health, Inc. (ELV) and Canadian Natural Resources Limited (CNQ).